Celularity (CELU) Asset Writedowns and Impairment (2020 - 2025)
Celularity (CELU) posted quarterly Asset Writedowns and Impairment of $3.0 million for Q4 2025, up 1194.04% year-over-year from $235000.0 in Q4 2024, and up 3203.06% quarter-over-quarter from -$98000.0 in Q3 2025.
Celularity (CELU) Asset Writedowns and Impairment (2020 - 2025) Analysis & Trends
Celularity (CELU) has reported Asset Writedowns and Impairment for 6 consecutive years, with $3.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment rose 1194.04% year-over-year to $3.0 million; the TTM figure through Dec 2025 stood at $2.9 million (up 532.39% YoY), while the FY2025 annual figure was $2.9 million, up 532.39% from the prior year.
- Asset Writedowns and Impairment rose to $3.0 million in Q4 2025 per CELU's latest filing, from -$98000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $107.2 million in Q2 2023 and bottomed at -$106.6 million in Q4 2023.
- Historically, Asset Writedowns and Impairment has averaged $355526.3 across 5 years, with a median of $174000.0 in 2021.
- Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment surged 49000.0% — and 2023, when it plunged 11993.64%.
- Celularity's Asset Writedowns and Impairment stood at $185000.0 in 2021, then jumped by 384.32% to $896000.0 in 2022, then slumped by 11993.64% to -$106.6 million in 2023, then surged by 100.22% to $235000.0 in 2024, then surged by 1194.04% to $3.0 million in 2025.
- Business Quant data shows CELU's Asset Writedowns and Impairment at $3.0 million in Q4 2025, -$98000.0 in Q3 2025, and $8000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.04 Mn |
| Dec 31, 2025 | 3.04 Mn |
| Sep 30, 2025 | -98,000.00 |
| Sep 30, 2025 | -98,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Mar 31, 2025 | -61,000.00 |
| Mar 31, 2025 | -61,000.00 |
| Dec 31, 2024 | 235,000.00 |
| Dec 31, 2024 | 235,000.00 |
| Sep 30, 2024 | -84,000.00 |
| Sep 30, 2024 | -84,000.00 |
| Jun 30, 2024 | 105,000.00 |
| Jun 30, 2024 | 105,000.00 |
| Mar 31, 2024 | 201,000.00 |
| Mar 31, 2024 | 201,000.00 |
| Dec 31, 2023 | -106.57 Mn |
| Dec 31, 2023 | -106.57 Mn |
| Jun 30, 2023 | 107.19 Mn |
| Jun 30, 2023 | 107.19 Mn |